Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
90% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. CPRX: No Debt )
CPRX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
85% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. CPRX: No Debt )
CPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 21.27
M-Score: -3.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -50.99
CPRX's ROE (%) is ranked higher than
53% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. CPRX: -50.99 )
CPRX' s 10-Year ROE (%) Range
Min: -1906.67   Max: -22.89
Current: -50.99

-1906.67
-22.89
ROA (%) -42.31
CPRX's ROA (%) is ranked higher than
52% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. CPRX: -42.31 )
CPRX' s 10-Year ROA (%) Range
Min: -766.07   Max: -22.19
Current: -42.31

-766.07
-22.19
ROC (Joel Greenblatt) (%) -1177.64
CPRX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. CPRX: -1177.64 )
CPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -108600   Max: -485.88
Current: -1177.64

-108600
-485.88
EBITDA Growth (3Y)(%) -6.30
CPRX's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. CPRX: -6.30 )
CPRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 42
Current: -6.3

0
42
EPS Growth (3Y)(%) -6.10
CPRX's EPS Growth (3Y)(%) is ranked higher than
68% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. CPRX: -6.10 )
CPRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.7   Max: 40.8
Current: -6.1

-33.7
40.8
» CPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CPRX Guru Trades in Q3 2013

Jim Simons 138,500 sh (New)
» More
Q4 2013

CPRX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q3 2014

CPRX Guru Trades in Q3 2014

Jim Simons 196,500 sh (New)
» More
Q4 2014

CPRX Guru Trades in Q4 2014

Steven Cohen 3,500,000 sh (New)
Steven Cohen 3,500,000 sh (unchged)
Steven Cohen 3,500,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.22
CPRX's P/B is ranked higher than
52% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. CPRX: 8.22 )
CPRX' s 10-Year P/B Range
Min: 2.33   Max: 26.33
Current: 8.22

2.33
26.33
Current Ratio 7.49
CPRX's Current Ratio is ranked higher than
91% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. CPRX: 7.49 )
CPRX' s 10-Year Current Ratio Range
Min: 2.25   Max: 54.56
Current: 7.49

2.25
54.56
Quick Ratio 7.49
CPRX's Quick Ratio is ranked higher than
92% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. CPRX: 7.49 )
CPRX' s 10-Year Quick Ratio Range
Min: 2.25   Max: 54.56
Current: 7.49

2.25
54.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.75
CPRX's Price/Net Cash is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPRX: 10.75 )
CPRX' s 10-Year Price/Net Cash Range
Min: 1.36   Max: 9.21
Current: 10.75

1.36
9.21
Price/Net Current Asset Value 8.21
CPRX's Price/Net Current Asset Value is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPRX: 8.21 )
CPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.24   Max: 8.6
Current: 8.21

1.24
8.6
Price/Tangible Book 8.22
CPRX's Price/Tangible Book is ranked higher than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPRX: 8.22 )
CPRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 10.09
Current: 8.22

1.24
10.09
Earnings Yield (Greenblatt) -4.80
CPRX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. CPRX: -4.80 )
CPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.8   Max: 0
Current: -4.8

-6.8
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CN2.Germany,
Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. In October 2012, the Company licensed the North American rights to Firdapse(tm), a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). CPP-115 is in the early stages of developing CPP-115, a GABA aminotransferase inhibitor that, based on its pre-clinical studies to date, it believe is a more potent form of vigabatrin, but may have fewer side effects than those associated with vigabatrin. CPP-109 was evaluated for the treatment of cocaine addiction. An academic investigator proof-of-concept study evaluating the use of CPP-109 for the treatment of Tourette syndrome is currently ongoing. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent Public O Feb 17 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX Jan 18 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, CPRX, BRT Jan 12 2015 
Largest Insider Buys of the Week Oct 25 2013 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Entry into a Material Definitive... Mar 27 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Financials Mar 20 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events Mar 19 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Mar 16 2015
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog Mar 16 2015
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results Mar 16 2015
Should You Buy Catalyst Pharmaceutical (CPRX) Ahead of Earnings? - Tale of the Tape Mar 16 2015
Catalyst reports 4Q loss Mar 16 2015
Catalyst reports 4Q loss Mar 16 2015
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results Mar 16 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 10-K, Annual Report Mar 13 2015
Will Inovio (INO) Disappoint This Earnings Season Again? - Analyst Blog Mar 13 2015
Will BioDelivery Sciences (BDSI) Impress this Earnings? - Analyst Blog Mar 13 2015
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog Mar 11 2015
What Awaits Synta Pharmaceuticals (SNTA) this Earnings? - Analyst Blog Mar 11 2015
Catalyst Pharmaceuticals to Present at the 27th Annual ROTH Conference Mar 09 2015
Catalyst Pharmaceuticals to Present at the 27th Annual ROTH Conference Mar 09 2015
CATALYST PHARMACEUTICAL PARTNERS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Mar 05 2015
Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for Treatment of... Mar 05 2015
Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for Treatment of... Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK